Intelligence Feed event · Equity · 2026-09-21

    Bristol Myers Squibb Growth Portfolio Reaches 60% of Q2 Revenue

    Question

    Bristol Myers Squibb Growth Portfolio Reaches 60% of Q2 Revenue

    Direct answer

    Bristol Myers Squibb delivered $12.9 billion in revenue in Q2, with EPS rising 153%. Commercial adoption across its newer pharmaceutical portfolio grew 15% year-over-year, now comprising nearly 60% of total revenues. The accelerated replacement of legacy off-patent revenues by higher-margin proprietary medicines is helping narrow the company's valuation discount relative to large-cap biopharma peers.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-21
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Bristol Myers Squibb Growth Portfolio Reaches 60% of Q2 Revenue”, revision 1, evidence through 2026-09-21. https://marketontology.com/market-events/2026-09-21/bristol-myers-squibb-growth-portfolio-reaches-60-of-q2-revenue-0df5eb

    EQUITY
    Bristol Myers Squibb Growth Portfolio Reaches 60% of Q2 Revenue
    Bristol Myers Squibb delivered $12.9 billion in revenue in Q2, with EPS rising 153%. Commercial adoption across its newer pharmaceutical portfolio grew 15% year-over-year, now comprising nearly 60% of total revenues. The accelerated replacement of legacy off-patent revenues by higher-margin proprietary medicines is helping narrow the company's valuation discount relative to large-cap biopharma peers.
    BMYXLV
    Impact
    67
    SEP 21
    SIG
    85%
    BMYXLV
    Bristol Myers Squibb Growth Portfolio Reaches 60% of Q2 Revenue
    Bristol Myers Squibb delivered $12.9 billion in revenue in Q2, with EPS rising 153%. Commercial adoption across its newer pharmaceutical portfolio grew 15% year-over-year, now comprising nearly 60% of total revenues. The accelerated replacement of legacy off-patent revenues by higher-margin proprietary medicines is helping narrow the company's valuation discount relative to large-cap biopharma peers.
    → Double-digit commercial expansion in BMY's newer product portfolio offsets patent expiration drag and improves consolidated EBITDA margins.
    Impact
    Bristol Myers Squibb delivered $12.9 billion in revenue in Q2, with EPS rising 153%. Commercial adoption across its newer pharmaceutical portfolio grew 15% year-over-year, now comprising nearly 60% of total revenues. The accelerated replacement of legacy off-patent revenues by higher-margin proprietary medicines is helping narrow the company's valuation discount relative to large-cap biopharma peers.
    Affected
    BMYXLV
    Transmission
    Double-digit commercial expansion in BMY's newer product portfolio offsets patent expiration drag and improves consolidated EBITDA margins.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BMYoperating cash flow growth via new drug revenue rampUp1-4wSource reports BMY Q2 revenue of $12.9B, 153% EPS growth, and 15% YoY growth in newer portfolio.
    XLVlarge-cap healthcare index earnings contributionUp1-4wBMY represents a core component within the US major pharmaceutical sub-index.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XLVUpagreed169.01 2026-09-21+0.52%+1.33%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month